Compare Novavax Inc (NVAX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Wix.Com Ltd — how do they compare? Novavax Inc trades at $8.15 (market cap $1.31B), while Wix.Com Ltd trades at $75.71 (market cap $2.88B). The key difference: Wix.Com Ltd is far larger — about 2.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| NVAX | WIX | |
|---|---|---|
Market Cap | $1.31B | $2.88B |
Sector | Health | Technology |
52-Week High | $11.19 | $184.24 |
52-Week Low | $6.22 | $40.43 |
Enterprise Value | $890.95M | $3.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.14, up 2.39% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $53 million in Q2 2026 but raised its full-year revenue outlook, driven by licensing milestones from its Sanofi partnership. Valuation ratios like P/E of 3.14 and EV/EBITDA of 1.72 appear low, yet negative profitability margins and cash flow challenges persist.
The outlook is mixed: analyst consensus is 74% buy with potential from partnerships, but risks include sustained losses, high debt, and competitive vaccine market pressure. Investors should weigh the low valuation against fundamental weaknesses and monitor execution on cost reductions and pipeline progress for upside catalysts.
WIX stock trades at $80.22, up 20.25% in 24 hours, reflecting strong momentum despite recent volatility. The company reported revenue growth to $1.99B in 2025, with a net income of $50.65M, though profitability remains inconsistent. Technical indicators show bullish signals, but RSI levels suggest potential overbought conditions. Multiple class action lawsuits filed in August 2026 allege securities fraud related to AI disclosures and a 27% share drop in May 2026.
Outlook is mixed: analyst consensus leans bullish with a $77.77 price target, but legal risks and negative cash flow trends pose significant headwinds. Investment opportunity hinges on execution amid competitive and litigation challenges, with volatility expected near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
